ストックスクリーナーアプリを入手
4.12
0.49%
0.02
プレマーケット:
4.12
Nervgen Pharma Corp (NGEN) 最新ニュース
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - GlobeNewswire
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - Yahoo! Finance Canada
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Australia
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026 - marketscreener.com
New drug may help spinal cord injury patients regain function and hope - WGN-TV
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
Johnson & Johnson receives CHMP positive opinion for AKEEGA - marketscreener.com
Analysts Expect Breakeven For NervGen Pharma Corp. (CVE:NGEN) Before Long - simplywall.st
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
NervGen Pharma Rings the Closing Bell - Nasdaq
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing - GlobeNewswire
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
NervGen Pharma to Begin Trading on Nasdaq - marketscreener.com
NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug - TipRanks
NervGen Pharma Gets Approval for Listing on Nasdaq - marketscreener.com
NervGen Pharma Brief: Begins Trading on Nasdaq Today - marketscreener.com
Sector Update: Health Care Stocks Edge Higher Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Mixed Late Afternoon - marketscreener.com
This Company’s Drug May Help Regenerate Injured Spinal Cords - Forbes
NervGen Pharma Files SEC Registration to Advance Strategic Growth - TipRanks
NervGen Pharma Announces Proposed Amendment to Warrants - Yahoo Finance
This Canadian biotech stock is looking to treat spinal cord injuries - Cantech Letter
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment - TipRanks
Data back spinal injury bid from Nervgen in phase Ib/IIa - BioWorld MedTech
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - TMX Newsfile
NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development - TipRanks
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - TMX Newsfile
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth? - Yahoo Finance
Pennsylvania man says experimental drug has helped him recover from cycling accident - CBS News
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma price target chopped at Research Capital - Cantech Letter
NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug - NAI500
TSX Penny Stocks To Consider In August 2025 - Yahoo Finance
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury - Yahoo Finance
NervGen Pharma is a buy, Research Capital says - Cantech Letter
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board - TMX Newsfile
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion - Yahoo Finance
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update - TMX Newsfile
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth - Yahoo Finance
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones - Yahoo Finance
Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury - NeurologyLive
NervGen Pharma: Risky, Yet Promising With Big Upside - Seeking Alpha
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):